About Atrin Pharma
Atrin Pharma is a Healthcare company based in Doylestown (United States) founded in 2011, and was acquired by Aprea in May 2022. Small molecule ATR pathway inhibitors and other therapeutics for multiple cancer indications. Atrin Pharma has raised $1.85 million across 2 funding rounds from investors including Aprea Therapeutics and Ben Franklin Technology Partners. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include C4 Therapeutics, Erasca and Revolution Medicines; 3 of its 3 listed competitors have raised funding.
Company details
Atrin Pharmaceuticals is a biopharmaceutical firm focused on the discovery and development of cancer therapeutics. Using technology developed and licensed in association with the University of Pennsylvania, Atrins bioresearch has developed a portfolio of drug candidates with multiple mechanisms of action. Atrins lead program is water-soluble, orally bioavailable small-molecule inhibitors of ATR for clinical application. Atrins pipeline of unique small molecules allows specific targeting of a broad spectrum of cancers (pancreatic, lung, ovarian, breast and colon). In addition to the ATR inhibitor series Atrins pipeline also contains two development candidates: ATRN-502, a p53 activator, and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. Atrins scientists have also invented the proprietary Atrize platform: a phenotypic FACS-based screening that is broadly applicable across RD, clinical applications and as a tool for personalized medicine.
- Headquarters Doylestown, United States
- Stage Acquired
- SectorsHealthcare
- Website atrinpharma.com
- Acquired by Aprea (May 2022)
- Total Equity Funding$1.85M (USD)
in 2 rounds
- Latest Funding Round$1.5M (USD), Seed
Apr 2016
- InvestorsAprea Therapeutics
& 1 more
- Acquired byAprea
(May 2022)
Funding Insights of Atrin Pharma
Atrin Pharma has successfully raised a total of $1.85M across 2 strategic funding rounds. The most recent funding activity was a Seed round of $1.5 million completed in April 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.85M
- Total Rounds 2
- Last Round Seed — $1.5M
- First Round $350,000
(Apr 2015)
- Investors Count 1
All 2 funding rounds of Atrin Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | $1.5M | Seed | – | – | – |
| Apr 2015 | $350,000 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Atrin Pharma
Atrin Pharma has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Aprea Therapeutics and Ben Franklin Technology Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Technology ecosystem growth is supported in Southeastern Pennsylvania. | sep.benfranklin.org | Philadelphia, United States | ||
Small molecule therapeutics are developed to target tumor suppressor proteins. | 2003 | aprea.com | Boston, United States |
Investor details for Atrin Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Atrin Pharma
15 people are tracked at Atrin Pharma (2 in leadership, 12 in board & advisors, 1 in team).
| Name | Role | Group |
|---|---|---|
Zeev Weiss | Chief Business Officer | Leadership |
Michel Afargan | Head, Pharmacology Development | Leadership |
Michael Grissinger | Director | Board & advisors |
Marc Duey | Director | Board & advisors |
Renold Capocasale | Director | Board & advisors |
Timothy Yap | Advisor | Board & advisors |
Karen E. Knudsen | Advisor | Board & advisors |
Zvi Gregorio Fridlender | Advisor | Board & advisors |
Bernard Rudnick | Director | Board & advisors |
Rifat Pamucku | Director | Board & advisors |
Jay Rosan | Director | Board & advisors |
Jeffrey Dayno | Director | Board & advisors |
Geoffrey I. Shapiro | Advisor | Board & advisors |
Eric Brown | Advisor | Board & advisors |
Molly Hansbarger | Scientist | Team |
Complete people profiles for Atrin Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Atrin Pharma
4 dated milestones of Atrin Pharma across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Atrin Pharma is founded.
- Funding First funding round of $350K.
- Funding Latest funding round, Seed, of $1.5M.
- Exit Acquired by Aprea.
Competitors of Atrin Pharma
Atrin Pharma has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and Revolution Medicines.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. |
Detailed competitors of Atrin Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Atrin Pharma (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Atrin Pharma
Complete news archive for Atrin Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Atrin Pharma
Atrin Pharma was founded in 2011 and raised its 1st funding round 4 years after it was founded.
Atrin Pharma is headquartered in Doylestown, United States. It is registered at Doylestown, Pennsylvania, United States.
Atrin Pharma is a funded company, having raised a total of $1.85M across 2 funding rounds to date. The company's 1st funding round was a Seed of $350K, raised on Apr 2015.
Atrin Pharmaceuticals is a biopharmaceutical firm focused on the discovery and development of cancer therapeutics. Using technology developed and licensed in association with the University of Pennsylvania, Atrins bioresearch has developed a portfolio of drug candidates with multiple mechanisms of action. Atrins lead program is water-soluble, orally bioavailable small-molecule inhibitors of ATR for clinical application. Atrins pipeline of unique small molecules allows specific targeting of a broad spectrum of cancers (pancreatic, lung, ovarian, breast and colon). In addition to the ATR inhibitor series Atrins pipeline also contains two development candidates: ATRN-502, a p53 activator, and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. Atrins scientists have also invented the proprietary Atrize platform: a phenotypic FACS-based screening that is broadly applicable across RD, clinical applications and as a tool for personalized medicine.
Atrin Pharma's top competitors include C4 Therapeutics, Erasca and Revolution Medicines.
Atrin Pharma has 2 investors. Key investors include Aprea Therapeutics, and Ben Franklin Technology Partners.
Yes. Atrin Pharma was acquired by Aprea in May 2022.